Abstract: The present invention relates to a method for intraoperatively or postoperatively detecting isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) gene mutations in glioma tumors and primers used in this method. In present invention, mismatched nucleotides were determined empirically, and the inventive primers were obtained by means of adapting the designs of the primers to detect the most common mutations in the IDH1 and IDH2 gene. The inventive primers comprise three 3? terminal nucleotides and said nucleotides mismatch to wild-type DNA (WT-DNA). However, only two of them, the penultimate and adjacent nucleotide, indicate mismatch to mutant DNA. The inventive method and primers provide a gene mutation detection method with high sensitivity and specificity, that allows for obtaining fast and reliable results.

Abstract: Phage displayed recombinant antibody library was developed and the library was screened against VEGFR-2. After screening and ELISA experiments two recombinant antibodies showing binding properties to VEGFR-2 was obtained. The difference of the two recombinant antibodies to the recombinant antibodies already developed was demonstrated by DNA sequence analysis. The inhibition effect of the two recombinant antibodies on endothelial cell proliferation was demonstrated with cell assays. Thus these recombinant antibodies might be used as VEGF related angiogenesis inhibitors.

Abstract: Phage displayed recombinant antibody library was developed and the library was screened against VEGFR-2. After screening and ELISA experiments two recombinant antibodies showing binding properties to VEGFR-2 was obtained. The difference of the two recombinant antibodies to the recombinant antibodies already developed was demonstrated by DNA sequence analysis. The inhibition effect of the two recombinant antibodies on endothelial cell proliferation was demonstrated with cell assays. Thus these recombinant antibodies might be used as VEGF related angiogenesis inhibitors.